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HypoxiaAim: Gastrins act as growth factors for the normal and neoplastic colorectal mucosa. The aim of this study was to
determine the role of gastrins in the response of human colorectal cancer (CRC) cells to hypoxia in vitro and
in vivo. Methods: Expression of the gastrin gene in the human CRC cell line LoVowas examined under normoxia
and hypoxia by quantitative PCR and by radioimmunoassay. Gastrin expression was knocked downwith shRNA,
and the effect on cell proliferationwasmeasured by cell counting, on cell apoptosis by annexin V staining, and on
cellmigration byBoyden chamber assay. The effect of gastrin knockdownon tumourigenesis inmouse xenografts
was analysed bymeasurement of tumour volumes and weights, and by immunohistochemistry. Results: Gastrin
gene expression in LoVo cellswas stimulated byhypoxia via binding of hypoxia-inducible factor-1α to the gastrin
promoter. The viability of gastrin knockdown cells exposed to hypoxia (1%O2) in vitrowas diminished because of
loss of resistance against hypoxia-induced apoptosis, and the effect was partly reversed by treatment with non-
amidated, but not amidated, gastrin. Conditioned medium from control LoVo cells under hypoxia simulated
proliferation but not migration, and the effect was blocked by an inhibitor of non-amidated gastrins, but not
by an inhibitor of amidated gastrins. In xenografts in mice exposed to hypoxia (10% O2) for 21 days, tumour
necrosis was signiﬁcantly increased by knocking down gastrin expression. Conclusion: These results provide
evidence that non-amidated gastrins are involved in the adaptation of CRCs to hypoxic microenvironments
through increasing resistance to apoptosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Tumour hypoxia, a reduction in the oxygen concentration in normal
tissue, occurs when solid tumours outgrow their local blood supply.
While tumours of 1–2 mm in diameter receive sufﬁcient oxygen by dif-
fusion across the capillary bed, rapid adaptation to hypoxia is necessary
to prevent cessation of growth and necrosis [1]. Signiﬁcantly, the capac-
ity of neovascularisation to supply oxygen generally lags behind tumour
demands and, consequently, hypoxia is a persistent feature of solid tu-
mourmicroenvironments [2]. Themaster regulator of cellular responses
to hypoxia is hypoxia-inducible factor-1 (HIF-1), a heterodimeric tran-
scription factor composed of a constitutively expressed β-subunit and
a hypoxia-inducible α-subunit [3]. HIF-1 directly regulates the expres-
sion of hypoxia-inducible genes via cis-acting hypoxia-response ele-
ments that contain a HIF-1 binding site [4]. The over-expression of
several potent mitogens, including vascular endothelial growth factorRC, colorectal cancer; Gamide,
progastrin; HB-EGF, heparin-
-1, hypoxia-inducible factor-1;
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in).(VEGF), in response to HIF-1 confers a selective proliferative advantage
on hypoxic tumour cells [5].
The hormone gastrin, in its fully processed amidated form (Gamide),
is well known as a potent stimulant of gastric acid secretion [6]. Howev-
er, gastrin gene expression is frequently increased in a variety of gastro-
intestinal cancers compared with normal mucosa [7,8]. In human CRC
cells, incomplete post-translational processing results in secretion of
the precursor peptides progastrin (PG) and glycine-extended gastrin
(Ggly) [9]. These non-amidated precursors, which are absent from
normal colonic mucosa, represent 90 to 100% of the gastrin peptides
constitutively secreted by human colonic tumours [9].
Upregulation of gastrin gene expressionmay contribute to colorectal
cancer (CRC) tumourigenesis. Increased concentrations of incompletely
processed gastrins are present in colonic polyps and adenocarcinomas
[10,11] and in the circulation of CRC patients [12], and exert mitogenic
effects on normal colorectal mucosa [13,14], and in CRC cell lines
in vitro [15,16] and in vivo [15,17]. Gastrins also have proangiogenic
properties. Tubule formation by human vascular endothelial cells is
enhanced by both Gamide and Ggly [18]. Treatment of human CRC
cell lineswith Ggly stimulated expression of themajor angiogenic factor
VEGF, and colons from transgenic mice overexpressing Ggly exhibited
higher levels of VEGF expression and greater microvessel density
compared to control mice [19].
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autocrine and possibly paracrine pathways [7]. Whereas Gamide acts
via the cholecystokinin 2 receptor (CCK2R) [6], the biological activity
of PG and Ggly is not blocked by CCK2R antagonists [20]. Non-
amidated gastrin precursors exert a spectrum of biological effects on a
variety of human CRC cell lines in vitro [21–23], and down-regulation
of endogenous gastrin expression suppressed xenograft tumourigenesis
in three human CRC cell lines (DLD-1, HCT116 and SW480) that express
high concentrations of PG and Ggly and low concentrations of Gamide
[15,17,24].
Data regarding the interplay between hypoxia and gastrin are limit-
ed. Circulating gastrin concentrations rise in rats [25] and newborn
calves [26] exposed to experimental hypoxia. In several gastrointestinal
cell lines, the gastrin transcript contains an internal ribosome entry site
that enables expression of gastrin peptides to continue when normal
translational mechanisms are inactivated under hypoxia [27]. We have
previously reported that gastrin expression in the human CRC cell line
LoVo is induced by hypoxia [28]. Therefore the aims of this study
were: ﬁrstly, to determine whether or not the upregulation of gastrin
gene expression by hypoxia was HIF-1-dependent; secondly, to exam-
ine whether hypoxia-induced gastrin gene products act as downstream
effectors of HIF-1-mediated cellular responses to hypoxia in LoVo cells;
and thirdly, to determine whether endogenous gastrin expression
represents a signiﬁcant adaptive response to chronic hypoxia in LoVo
cell xenografts in mice.
2. Methods
2.1. Cell line
The human CRC cell line LoVo was obtained from the ATCC, and was
maintained in Ham's F-12K medium containing 10% foetal bovine
serum (FBS) (Life Technologies, San Diego, CA, USA) at 37 °C in 5%
CO2. Although some clones of LoVo cells express functional CCK2 recep-
tors [22,29], others, including the LoVo cells used in this study, do not
[30,31].
2.2. Animals
Male 8 week-old Severe Combined Immunodeﬁciency (SCID) mice
were obtained from the Walter and Eliza Hall Institute (Melbourne,
Australia) and housed at the accredited Austin Health Bioresources
Facility in sealed laminar airﬂow cabinets under pathogen-free condi-
tions on a 12-hour light/dark cycle. All procedures were performed
under sterile conditions. Mice were fed autoclaved standard chow
(Ridley Agriproducts, Melbourne, Australia) and water ad libitum.
2.3. Peptides
Recombinant human progastrin6-80was prepared as previously de-
scribed [32]. Ggly andGamidewere synthesised byAuspep (Melbourne,
Australia).
2.4. shRNA transfection
Two predesigned and validated Mission® short hairpin RNA (shRNA)
plasmids for human HIF-1α (clone numbers TRCN0000003810 and
TRCN0000010819), ﬁve predesigned but unvalidated Mission™ short
hairpin RNA (shRNA) plasmids for human gastrin (TRCN0000242963,
TRCN0000242964, TRCN0000242965, TRCN0000242966 and TRCN
0000242967), and a scrambled shRNA control (SHC002) were pur-
chased from Sigma-Aldrich (Castle Hill, NSW, Australia). LoVo cells
were transfected with the shRNA plasmids using the Neon transfec-
tion method, and transfectants were selected with puromycin, as
described previously [28].2.5. Hypoxia treatment
Cells were exposed to true hypoxia by incubation at 37 °C in a sealed
humidiﬁed chamber containing 94% N2, 5% CO2 and 1% O2. Oxygen
concentrations in the hypoxia chamber were automatically adjusted
by an electronic oxygen controller (ProOx Model 110, Biospherix,
Redﬁeld, NY, USA). Cells were exposed to chemical hypoxia by incuba-
tion at 37 °C in serum-free medium containing 300 μM CoCl2 in a
humidiﬁed incubator with 95% air and 5% CO2 [28].
2.6. Conditioned medium
Cells were seeded onto 100 mm culture dishes (BD Biosciences,
Franklin Lakes, NJ, USA) in a medium containing 10% FBS at a density
of 4 million cells per dish and incubated for 6 h to allow adhesion to
the dish surface. The medium was then aspirated and the cells were
washed once with serum-free medium. Fresh serum-free medium
(5 mL) was added to each dish and the cells were exposed to hypoxia
or normoxia as described above. After 24 h, the medium was aspirated
and centrifuged at 1100 rpm for 2 min at 25 °C to remove cell debris,
and the supernatant was collected. For cell migration assays, ﬁlter-
sterilised 10% (w/v) BSA (Sigma-Aldrich) in serum-free medium was
added to the conditionedmedium to a ﬁnal concentration of 0.1% (w/v).
2.7. Cell proliferation, apoptosis and migration
Cells were counted in duplicate using a Countess™ Automated Cell
Counter (Life Technologies) according to the manufacturer's instruc-
tions. Apoptosis was quantiﬁed using an Annexin V-FITC Apoptosis De-
tection Kit (BD Biosciences) according to the manufacturer's protocol.
Samples were analysed using a FACSDiva™ ﬂow cytometer with
FACSDiva™ software (BD Biosciences). Cell migration was assessed
using a Boyden chamber as previously described [33].
2.8. Xenograft growth
Ethics approval was obtained from the Austin Health Animal Ethics
Committee to perform xenograft tumour experiments on SCID mice
under conditions of hypoxia (Project A2012-04564). Bilateral tumour
xenografts were initiated by subcutaneous injection of 3 × 106 cells in
100 μL of medium using a 26 G needle. In each SCID mouse, gastrin
knockdown cells were injected in the left ﬂank and scrambled cells in
the right ﬂank. The animals were weighed and tumours weremeasured
in two dimensions using a digital calliper thrice weekly. Tumour
volumes (mm3) were calculated using the formula:
Tumour Volume ¼ Length Widthð Þ2  π=6:
Tumours were allowed to grow until the average tumour volume
was 50–60 mm3. The mice were then randomised into two equal
groups (N = 10) to receive either normobaric normoxia (21% O2) or
normobaric hypoxia (10% O2). The mice were exposed to hypoxia by
placing their cages into a clear plastic chamber, within which the oxy-
gen concentration was automatically adjusted by an electronic oxygen
controller (ProOx Model 110, Biospherix) by infusion of nitrogen
balanced against an inward leak of air through holes in the chamber.
The mice in the normoxia treatment group were kept in sealed laminar
airﬂow cabinets. The health of all mice was recorded using an animal
health scoring system. The mice were sacriﬁced with an inhalation
overdose of isoﬂurane. Blood samples were collected by cardiac punc-
ture and tumours were excised and their wet weights were recorded.
One half of each tumour was snap frozen in liquid nitrogen and stored
at−80 °C for RNA and protein extraction, and the other was ﬁxed in
10% formalin for parafﬁn embedding.
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Tumours were ﬁxed, sectioned and stained as previously described
[33]. For quantiﬁcation of tumour necrosis, whole ﬁeld images of each
haematoxylin and eosin (H&E)-stained tumour section were acquired
at 2× magniﬁcation. The total cross-sectional area and the necrotic
area of the tumour (mm2) were measured using Image-Pro Plus 6.0
software (Media Cybernetics, Silver Spring, MD, USA). The percentage
of tumour necrosis was calculated as the ratio of the necrotic area to
the total tumour area multiplied by 100.
For immunohistochemical staining [33], the following primary anti-
bodies were used at the indicated dilutions: anti-human Ki-67 rabbit
polyclonal antibody (1:100, 18-0191Z, Life Technologies), anti-human
HIF-1α rabbit polyclonal antibody (1:100, H-206/sc-10790, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-human active caspase-3
rabbit polyclonal antibody (1:1000, AF835, R&D Systems, Minneapolis,
MN, USA), and anti-mouse CD34 rat monoclonal antibody (1:500,
MCA1825GA, AbD Serotec, Raleigh, NC, USA) with anti-rat rabbit poly-
clonal antibody (1:100, E0468, Dako, Glostrup, Denmark). The following
two secondary antibodies were then used at the indicated dilutions:
anti-rabbit goat polyclonal antibody conjugated to a horseradish perox-
idase (HRP)-labelled polymer (1:200, K4011, Dako), anti-FITC rabbit
polyclonal antibody conjugated toHRP (1:100, Natural Pharmacia Inter-
national, Burlington, MA, USA).
2.10. Western blotting
Cell extracts were prepared, and the extracted proteins were
resolved by SDS-polyacrylamide gel electrophoresis and blotted onto
nitrocellulose membranes, as described previously [28]. HIF-1α and
GAPDH protein expression was detected with HIF-1α (BD Biosciences)
and anti-GAPDH antibodies (Cell Signalling, Mulgrave, VIC, Australia),
respectively.
2.11. RNA preparation and quantitative PCR
Total RNA was isolated, cDNA was synthesised and gastrin gene ex-
pressionwas quantitated by real-time PCR, as described previously [28].
2.12. Statistical analysis
Statistics were analysed using the programme SigmaPlot version
12.0 (Systat Software Inc., San Jose, CA, USA). The results are
expressed as mean ± SEM unless otherwise stated. All data sets
were ﬁrst tested for normality by the Shapiro–Wilk method. Where
the data was normally distributed, single statistical comparisons
were made by Student's t-tests with the level of signiﬁcance set at
p b 0.05. The statistical signiﬁcance is indicated by the following
symbols: ***, p b 0.001; **, 0.001 b p b 0.01; *, 0.01 b p b 0.05.
3. Results
3.1. Hypoxia increases HIF-1α protein expression in the human CRC cell line
LoVo
To establish the involvement of HIF-1α in the response of thehuman
CRC cell line LoVo to hypoxia, HIF-1α protein expression wasmeasured
byWestern blotting. HIF-1α protein expression in LoVo cells was signif-
icantly increased 4.5-fold by both true hypoxia (1% O2) and chemical
hypoxia (300 μM CoCl2) compared to untreated controls (Fig. 1A).
HIF-1α protein expression in response to hypoxia in LoVo cells stably
transfected with either of two different HIF-1α shRNAs (shRNA1 and
shRNA2) was signiﬁcantly reduced 3.5-fold compared to a scrambled
shRNA control (Fig. 1B).3.2. Induction of gastrin expression by hypoxia is dependent on HIF-1α
To investigate whether gastrin gene expression in LoVo cells was
stimulated by exposure to hypoxia, concentrations of gastrin mRNA
were analysed by quantitative real-time RT-PCR. Expression of gastrin
mRNA in LoVo cells exposed to true hypoxia was signiﬁcantly increased
6-fold compared to untreated controls (Fig. 1C). In response to chemical
hypoxia there was a modest 1.5-fold increase in gastrin gene expres-
sion. The concentrations of endogenous PG and Gamide in the cell ex-
tract and conditioned medium of LoVo cells treated with hypoxia
were also increased as assessed by radioimmunoassay (data not
shown). Under normoxic conditions, there was a small but signiﬁcant
reduction in gastrin gene expression in LoVo cells stably transfected
with either HIF-1α shRNA compared to scrambled controls (Fig. 1D).
Hypoxia resulted in a signiﬁcant 5-fold increase in gastrin mRNA
expression in scrambled shRNA transfectants compared to normoxic
controls. However, in cells in which HIF-1α expression had been
knocked down, hypoxia produced no signiﬁcant change in gastrin
gene expression compared to scrambled controls under normoxic
conditions.
The promoter of the human gastrin gene contains seven putative
hypoxia response elements homologous with the HIF-1 binding
consensus sequence [28]. To examine whether the hypoxia respon-
siveness of the human gastrin promoter was mediated via HIF-
binding sites, the activity of a construct in which all seven putative
hypoxia response elements had been deleted was analysed in a
dual-luciferase reporter assay. LoVo cells transiently co-transfected
with either a full-length gastrin promoter construct (1147pGASLuc)
or a 5′-truncated construct (365pGASLuc) were exposed to hypoxia
for 16 h. The activity of the full-length gastrin promoter was signiﬁ-
cantly upregulated 2.5-fold by hypoxia and this response was
abolished in the 5′-truncated construct that contained no putative
HIF-binding sites (Fig. 1E).
3.3. Knockdown of gastrin mRNA expression reduces proliferation and in-
creases apoptosis in the human colorectal cancer cell line LoVo under
hypoxia
To assess the role of gastrin in the response of LoVo cells to hyp-
oxia, cells were transfected with plasmids expressing one of ﬁve dif-
ferent shRNAs against gastrin or with a non-targeting scrambled
shRNA control. The shRNA clone TRCN0000242967, which targets
nucleotides 120–140 of gastrin mRNA, reduced gastrin mRNA ex-
pression in two independent clones (Gastrin KD1; Gastrin KD2)
(Fig. 2A). Under conditions of normoxia, there was a signiﬁcant
93% reduction in gastrin gene expression in both knockdown clones
relative to scrambled shRNA controls. Treatment with hypoxia for 16
h resulted in a signiﬁcant 4-fold increase in gastrin mRNA expression
in scrambled shRNA transfectants compared to normoxic controls.
Although gastrin mRNA expression in both knockdown clones was
upregulated in response to exposure to hypoxia for 16 h, it remained
signiﬁcantly less than that of scrambled shRNA transfectants under
normoxic conditions. The concentrations of endogenous PG in the cell
extracts and conditioned media of LoVo cells stably transfected with
gastrin shRNA were also reduced as assessed by radioimmunoassay
(Supplementary Fig. 1).
To assess the effect of gastrin knockdown on the viability and prolif-
eration of LoVo cells under hypoxia, the numbers of viable gastrin
knockdown and scrambled control LoVo clones were assessed by auto-
mated cell counting after incubation in low-serum medium (1% FBS)
under normoxia or hypoxia. Under conditions of normoxia, the prolifer-
ation of gastrin knockdown clones was signiﬁcantly reduced compared
to scrambled controls (Fig. 2B). Under hypoxia, the proliferation
of scrambled control cells was signiﬁcantly reduced compared to
normoxic controls. In both gastrin knockdown clones, exposure to hyp-
oxia resulted in a gradual reduction in cell viability that was signiﬁcant
Fig. 1. Expression of HIF-1α shRNA signiﬁcantly decreases hypoxia-dependent gastrin induction in the human CRC cell line LoVo. A.Western blot analysis of HIF-1α protein expression in wild-
type LoVo cells treated with either hypoxia (1% O2) or 300 μM cobalt chloride (CoCl2) for 16 h compared to untreated controls. B. Western blot analysis of HIF-1α protein expression under
normoxia (N, 21% O2) or hypoxia (H, 1% O2) in LoVo cells stably expressing a scrambled shRNA or two different shRNAs that target HIF-1α. Values were normalised to GAPDH and ratios
were calculated relative to untreated controls. C. Quantitative RT-PCR analysis of gastrinmRNA expression inwild-type LoVo cells treatedwith either hypoxia (1% O2) or 300 μMcobalt chloride
(CoCl2) for 16 h compared to untreated controls. D. Quantitative RT-PCR analysis of gastrin mRNA expression under normoxia (21% O2) or hypoxia (1% O2) in LoVo cells stably expressing a
scrambled control shRNA or two different shRNAs that target HIF-1α. Transcription levels are expressed as fold change relative to scrambled shRNA transfectants under normoxia. E. LoVo
cells were transiently transfected with 5′-deletion constructs of the human gastrin promoter region fused to the ﬁreﬂy luciferase reporter gene. All putative HIF-1 responsive elements
(HREs, black vertical lines) were retained within the 1147pGASLuc construct, but deleted in the 365pGASLuc construct. Promoter activities of the deletion constructs were measured in co-
transfected LoVo cells exposed to hypoxia (1%O2) for 16h. Transfection efﬁciencywasnormalised toRenilla luciferase activity. Thepromoter activitywas calculated as the fold increase of relative
luciferase activity compared to the corresponding untreated normoxic control. Data aremeans±SEMwith sample size, N=3 (duplicate samples). *, p b 0.05; **, 0.001 b p b 0.01; ***, p b 0.001.
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Fig. 2. Knockdown of gastrin mRNA expression reduces proliferation and increases apoptosis in the human CRC cell line LoVo under hypoxia. A. Quantitative RT-PCR analysis of gastrin
mRNA expression in LoVo cells stably expressing either a scrambled shRNA or a shRNA that targets gastrin (Gastrin KD1; Gastrin KD2) under conditions of normoxia (21% O2) or hypoxia
(1% O2) for 16 h. Transcription levels are expressed as the fold change relative to scrambled shRNA transfectants under normoxic conditions. *, p b 0.05; **, 0.001 b p b 0.01; ***, p b 0.001,
versus scrambled shRNA transfectants under the same conditions. B. Proliferation of gastrin KD1 or scrambled control LoVo cells was measured under normoxia or hypoxia. Cells were
incubated in low-serummedium (1% FBS) for 24, 48 or 72 h, and viable cells were counted using a Trypan blue exclusion assay. *, p b 0.05; **, 0.001 b p b 0.01; ***, p b 0.001 versus scram-
bled normoxia. #, p b 0.05; ##, 0.001 b p b 0.01 versus scrambled hypoxia. Similar results were obtained for the gastrin KD2 clone. C. Flow cytometric analysis of apoptosis in gastrin KD or
scrambled control LoVo cells. Cellswere incubated in low-serummedium (1% FBS) under hypoxia for 24, 48 or 72 h. The percentage of cells undergoing early apoptosiswas determined by
FACS analysis after annexin V/PI staining. ***, p b 0.001 versus scrambled controls. D. Gastrin KD or scrambled control LoVo cells were incubated in low-serummedia (1% FBS) without or
with either 10 nM progastrin (PG), 10 nM glycine-extended gastrin (Ggly) or 10 nM Gamide (GA) under hypoxia for 24 h. The percentage of annexin V-positive/PI-negative cells was
determined by FACS analysis and normalised to scrambled control cells exposed to 24 h of hypoxia to generate an apoptotic index. The apoptotic index represents the fold change in
the proportion of cells sensitive to hypoxia-inducible apoptosis relative to the scrambled control, with an apoptotic index of one (indicated by the horizontal white bar) representing
complete rescue of the knockdown phenotype. Treatment with the non-amidated gastrins PG (10 nM) or Ggly (10 nM) resulted in a signiﬁcant reduction in the apoptotic index of gastrin
KD cell lines exposed to hypoxia for 24 h (*, p b 0.05; **, 0.001 b p b 0.01 versus untreated controls), and thus partially rescued the knockdown phenotype. Treatment with Gamide did not
signiﬁcantly alter the apoptotic index of either gastrin KD cell line. Data are means ± SEM with sample size, N = 3 (duplicate samples).
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that the viability of LoVo cells under conditions of hypoxia is reduced
by knocking down endogenous gastrin expression.
To assess the relative contribution of apoptosis to the reduction in cell
viability observed in the gastrin knockdown cell lines, the ratio of cells
undergoing early apoptosis was measured by ﬂow cytometry with
annexin V staining and PI uptake as markers. In scrambled cells, hypoxia
treatment resulted in a small time-dependent increase in the ratio of
early apoptotic cells (Fig. 2C). In both gastrin knockdown clones there
was a signiﬁcantly higher ratio of early apoptotic cells at all time points
compared to scrambled controls, and this difference was most marked
after 72 h of hypoxia. This result suggests that knocking down gastrin
expression sensitises LoVo cells to hypoxia-induced apoptosis.
To test the ability of exogenous PG, Ggly andGamide to restore resis-
tance to hypoxia-induced apoptosis in two gastrin knockdown LoVo
clones, cells were incubated under hypoxic conditions in low-serummedium without or with 10 nM PG, 10 nM Ggly or 10 nM Gamide.
After 24 h the ratio of cells undergoing early apoptosis was measured
using ﬂow cytometry with annexin V staining and PI uptake asmarkers.
Treatment with 10 nM PG or Ggly signiﬁcantly reduced the percentage
of early apoptotic cells in both gastrin knockdown clones compared to
untreated controls. In contrast, treatment with 10 nM Gamide did not
signiﬁcantly alter the percentage of cells sensitised to hypoxia-
inducible apoptosis by gastrin knockdown (Fig. 2D).
3.4. Conditioned medium from control LoVo cells under hypoxia stimulates
proliferation but not migration
To test the hypothesis that soluble factors secreted by LoVo cells under
conditions of hypoxia might be responsible for the observed effects on
proliferation, conditionedmedia was isolated from serum starved scram-
bled and gastrin knockdown LoVo clones cultured for 24 h under
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bated with conditioned media under normoxic conditions for 24 h
and viable cells were counted. Hypoxia-conditioned medium from
scrambled cells signiﬁcantly stimulated (92 ± 17%) the proliferation
of normoxic quiescent scrambled cells (Fig. 3A). Viable cell numbers
were also signiﬁcantly increased following treatment with hypoxia-
conditioned media derived from Gastrin KD1 (33 ± 11%) or KD2 cells
(37±9%). However, themitogenic activity of hypoxia-conditionedme-
dium from either gastrin knockdown clone was signiﬁcantly less than
that derived from scrambled cells. These observations suggest that the
active constituents of hypoxia-conditioned media may include PG-
derived peptides.
To determine which PG-derived peptides were among the active
constituents of conditioned media, the effect of selective Ggly and
Gamide receptor antagonists was investigated. Bi3+ ions selectively
inhibit the biological activity of Ggly in vitro without signiﬁcant effectFig. 3. Conditionedmedium from control LoVo cells under hypoxia simulates proliferation but n
and treatedwith conditionedmedium for 24h under normoxia (21%O2). Conditionedmedium
exposed to normoxia or hypoxia (1% O2) for 24 h in serum-free medium. Viable cells were cou
treatedwith conditionedmedium fromnormoxic scrambled cells. *, p b 0.05 and **, 0.001 b p b 0
versus treatment with conditioned medium from scrambled hypoxic cells. B. Proliferation of qu
dium for 24 h under normoxia. Conditionedmediumwas derived from scrambled LoVo cells ex
dium alone (control), conditioned medium containing 50 nM bismuth citrate, or conditioned m
(50 nM). Viable cells were counted using a Trypan blue exclusion assay, and values are presente
bled cells. *, p b 0.05 versus treatmentwith control conditionedmedium from scrambled normo
of gastrin KD or scrambled control LoVo cells was assessed using a transwell migration assay.
coated transwell inserts and incubated under normoxic or hypoxic conditions. After 24 h, mig
the number of cells in 24 high power ﬁelds (20×magniﬁcation)was counted, and values are pr
scrambled normoxia. D.Migration of scrambled control LoVo cells treatedwith conditionedmed
media were derived from scrambled or gastrin knockdown LoVo cells line exposed to normoxi
tioned medium containing 0.1% BSA or serum-free medium containing 0.1% BSA (untreated con
containing the same medium and incubated under normoxia. Migration was assessed as descron the actions of Gamide [34]. The addition of 50 nM bismuth citrate
signiﬁcantly decreased the mitogenic efﬁcacy of hypoxia-conditioned
medium, with a reduction in the increase in viable cell numbers
from 92 ± 17% to 37 ± 13%, but had no signiﬁcant effect on
normoxia-conditioned medium (Fig. 3B). In contrast prior treatment
of hypoxia-conditioned medium with a CCK2 receptor antagonist
(50 nM RP73870A, Rhône-Poulenc Rorer, Vitry-sur-Seine, France)
had no effect on the proliferative response of normoxic scrambled
LoVo cells to either normoxia- or hypoxia-conditioned medium.
These observations suggest that the active constituents of hypoxia-
conditioned media include Ggly but not Gamide.
To test the effect of hypoxia-conditioned media on migration, the
ability of gastrin knockdown and scrambled control LoVo clones to mi-
grate was assessed using a transwell assay under normoxia or hypoxia.
All three LoVo clones demonstrated spontaneous migratory activity,
which increased two-fold when cells were incubated under hypoxicot migration. A. Proliferation of quiescent LoVo cells stably expressing a scrambled shRNA
wasderived from scrambled or gastrin knockdown (Gastrin KD1; GastrinKD2) LoVo clones
nted using a Trypan blue exclusion assay, and values are presented as a percentage of cells
.01 versus treatmentwith conditionedmedium from scrambled normoxic cells; #, p b 0.05
iescent LoVo cells stably expressing a scrambled shRNA and treated with conditioned me-
posed to hypoxia for 24 h in serum-freemedium. Cells were treatedwith conditionedme-
edium following pre-treatment for 30 min with the CCK2 receptor antagonist RP73870A
d as a percentage of cells treatedwith control conditionedmedium from normoxic scram-
xic cells. Data aremeans± SEMwith sample size, N= 5 (duplicate samples). C. Migration
Cells suspended in serum-free medium containing 0.1% BSA were plated on ﬁbronectin-
rating cells were visualised using a modiﬁed Romanowsky–Wright stain. For each insert,
esented as a percentage of scrambled cells exposed to normoxia. **, 0.001 b p b 0.01 versus
ium for 24 h under normoxiawas assessed using a transwell migration assay. Conditioned
a or hypoxia for 24 h in serum-free medium. Scrambled control cells suspended in condi-
trol) were seeded onto ﬁbronectin-coated transwell inserts which were placed into wells
ibed above. Data are means ± SEM with sample size, N = 3 (duplicate samples).
2477D.A. Westwood et al. / Biochimica et Biophysica Acta 1843 (2014) 2471–2480conditions (Fig. 3C). No signiﬁcant difference in migratory activity was
observed between the gastrin knockdown and scrambled control clones
under either normoxia or hypoxia. Furthermore the migratory activity
of normoxic scrambled cells was unaltered by normoxia- or hypoxia-
conditioned media from either a scrambled clone or a gastrin knock-
down clone(Fig. 3D).
3.5. Hypoxia does not affect proliferation or apoptosis in human colorectal
tumour xenografts derived from gastrin knockdown or scrambled control
LoVo clones
Tumour xenografts were initiated by subcutaneous injection of gas-
trin knockdown and scrambled control LoVo clones into opposite ﬂanks
of twenty mice. Tumours were established (50–60 mm3) in all injected
animals after 14 days, and mice were then randomised into two equal
groups and exposed to either normoxia or continuous hypoxia for
21 days. Exposure to hypoxia signiﬁcantly increased the hypoxic frac-
tion of both scrambled and gastrin knockdown xenografts (Supplemen-
tary Fig. 2). In the normoxia group, there was no signiﬁcant change inFig. 4. Hypoxia does not affect proliferation or apoptosis in human CRC xenografts derived fr
subcutaneous xenografts derived from a gastrin knockdownLoVo clone on oneﬂank and a scram
to either normoxia (21% O2) or hypoxia (10% O2) for 21 days. Themice were weighed and tum
(one from each group)met ethical end-point criteria for euthanasia andwere culled on day 11. A
tumour wet weight was recorded. A. Tumour volumes are given asmeans± SEMwith sample
recorded at necropsy. C. Cell proliferation in tumourswasmeasured by immunohistochemical d
age of Ki-67 positive cells in ﬁve representative high power ﬁelds within the viable area of each
four groups. D. Apoptosis within the peri-necrotic zone of each tumour was assessed by active c
positive cells in ﬁve representative high power ﬁelds. Data are means ± SEM with sample sizemean body weight between the beginning and end of the study period
(24.4 ± 0.8 g versus 24.8 ± 0.8 g, respectively). In the hypoxia group,
there was a signiﬁcant reduction in mean body weight from 25.5 ±
0.7 g to 22.1 ± 0.7 g, and at the experimental end-point, the mean
weight of the mice in the hypoxia group was signiﬁcantly less than
that of the normoxia group.
Tumours in the four groups (scrambled normoxia, gastrin knock-
down normoxia, scrambled hypoxia and gastrin knockdown hypoxia)
had similar growth curves (Fig. 4A) and there was no signiﬁcant differ-
ence in ﬁnalmean tumour volumes orweights between the four groups
(Fig. 4B), or in mean serum Gamide concentration in the normoxia
group compared to the hypoxia group (9.7 ± 1.3 fmol/mL versus 9.5 ±
0.7 fmol/mL, respectively). The proliferating cell fraction in xenografts,
determined by calculating the percentage of Ki-67-positive cells within
regions of viable tumour, was not signiﬁcantly different between the
four groups (Fig. 4C). Similarly, there was no signiﬁcant difference in
peri-necrotic apoptosis, determined by calculating the percentage of ac-
tive caspase-3-positive cells in the peri-necrotic zone, between the four
groups (Fig. 4D). Furthermore there was no signiﬁcant difference in theom gastrin knockdown or scrambled control LoVo clones. Twenty mice bearing bilateral
bled control LoVo clone on the otherwere randomised into two equal groups and exposed
our dimensions were measured using a digital calliper three times per week. Two animals
t the experimental end-point, themicewere sacriﬁced and tumours were excised and the
size, N= 10 (day 0 to day 11) and N= 9 (day 14 to day 21). B. Tumour wet weights were
etection of Ki-67. The proliferating cell fractionwas determined by calculating the percent-
tumour. There was no signiﬁcant difference in the proliferating cell fraction between the
aspase-3 immunohistochemistry. The apoptotic index was calculated as the percentage of
, N = 9.
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trin knockdown compared to scrambled xenografts in either the
normoxia or hypoxia group (Supplementary Fig. 3).
3.6. Gastrin knockdown increases tumour necrosis in the presence of
hypoxia
Macroscopic skin changes indicating underlying tumour necrosis
[35] were visible in 6 of 9 gastrin knockdown xenografts in the hypoxia
group at the experimental end-point (Fig. 5B). None of the scrambled
xenografts in the hypoxia group, and none of the gastrin knockdown
or scrambled xenografts in the normoxia group, exhibited these chang-
es (Fig. 5A). Viable tumours exhibited a well-differentiatedmorphology
in H&E-stained sections, with extensive acinar-like formations (Fig. 5C),
consistentwith descriptions ofmurine subcutaneous LoVoxenografts in
the literature [36]. Tumour necrosis, present as areas of homogenous
eosinophilia (Fig. 5D), was observed in all of the xenografts. A peri-
necrotic zone, containing cells displaying shrunken eosinophilic cyto-
plasms and condensed pyknotic nuclei (Fig. 5E), marked the interface
between areas of viable and necrotic tumours (Fig. 5F). Using whole
ﬁeld images of H&E-stained tumour sections (Fig. 5G), tumour necrosis
(including the peri-necrotic zone) was calculated as a percentage of the
total cross-sectional area of each tumour. In the normoxia group, theFig. 5. Gastrin knockdown increases tumour necrosis in the presence of hypoxia. Subcutaneou
exposed to normoxia (21% O2) or hypoxia (10% O2) for 21 days. A, B. Representative mice bear
normoxia (A) and hypoxia (B) groups. The appearance of the skin overlying the gastrin KD xen
[35]. C. A representative photomicrograph of a scrambled xenograft from the hypoxia group is
D–G. Tumour sections from a gastrin knockdown xenograft were stainedwith haematoxylin an
with extensive acinar-like formations (D). Tumour necrosis was present as areas of homogenou
cytoplasms and condensed pyknotic nuclei (F), marked the interface between areas of viable an
25 μm (F–G). H. Tumour necrosis (including the peri-necrotic zone) was calculated as a percen
means ± SEM with sample size, N = 9.difference in necrosis between gastrin knockdown tumours and scram-
bled tumours (36.5 ± 4.6% versus 28.2 ± 3.5%, respectively) did not
reach statistical signiﬁcance. In the hypoxia group, however, there
was signiﬁcantly more necrosis in the gastrin knockdown tumours
(51.8 ± 2.6%) compared to the scrambled tumours (27.6 ± 2.1%)
(Fig. 5H).4. Discussion
Gastrin gene expression in CRC cells is upregulated by cell-intrinsic
factors, such as mutations in the APC/β-catenin and KRAS pathways
[37]. However, the effects of cell-extrinsic factors, such as oxygen
concentration, on gastrin gene regulation remain largely unexplored,
although hypoxia is a potent stimulant of gastrin gene expression in
the human CRC cell line LoVo [28]. Here we report that cobalt chloride
also up-regulatedHIF-1α expression to a degree similar to true hypoxia.
Induction of HIF-1α expression by cobalt chloride has previously been
reported in the human CRC cell lines HT29, HCT116 and SNUC4 [38].
In LoVo cells, the observation that basal gastrin mRNA expression was
signiﬁcantly reduced by knockdown of HIF-1α (Fig. 1D) supports an
interaction between HIF-1 and the gastrin promoter under normoxic
conditions.s LoVo xenografts derived from gastrin KD or scrambled control cells were grown in mice
ing scrambled control (black arrows) and gastrin KD xenografts (white arrows) from the
ograft in the mouse exposed to hypoxia for 21 days indicates underlying tumour necrosis
shownwith the areas of tumour necrosis highlighted with a solid yellow line. Bar, 500 μm.
d eosin for histological analysis. Viable tumour exhibited awell-differentiatedmorphology
s eosinophilia (E). A peri-necrotic zone, containing cells displaying shrunken eosinophilic
d necrotic tumours (G). Representative photomicrographs are shown. Bar, 10mm (D–E);
tage of the total cross-sectional area of each tumour (*, p b 0.05; ***, p b 0.001). Data are
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tigated using LoVo cells stably expressing shRNA directed against the
gastrin gene. LoVo cells were chosen for these experiments because
the gastrin gene is constitutively expressed at high levels [19] and is
potently induced by hypoxia [28], and because the biological effects of
down-regulating gastrin gene expression are most marked in human
CRC cell lines that constitutively express high levels of gastrins [15,39].
Under normoxia, proliferation of both gastrin knockdown clones was
signiﬁcantly reduced compared to scrambled controls. This observation
supports the hypothesis that an autocrine and/or intracrine gastrin loop
makes an important contribution to the basal growth of LoVo cells.
Under hypoxia, however, scrambled cell proliferation was drastically
reduced despite gastrin gene expression being up-regulated four-fold
compared to normoxic controls.
A recent study found that exposure of wild-type LoVo cells to 1%
hypoxia for 10 days signiﬁcantly impaired proliferation with no detect-
able effect on cell viability [40]. Similarly, in this study, no reduction in
the number of viable scrambled cells was observed after 72 h of hypox-
ia. However, in both gastrin knockdown clones a gradual reduction in
cell viability was noted. Cell death due to hypoxia may occur as a result
of apoptosis or necrosis [41]. Although previously thought to represent
two distinct mechanisms of cell death, apoptosis and necrosis are now
considered to be two extremes of a continuum of cell demise [42] and,
in the early phases of the cell death process, share common second
messengers, activators and inhibitors [43].
PG, Ggly and Gamide have been shown to promote resistance
against a number of apoptotic stimuli in a wide range of human gastro-
intestinal cancer cell lines [23,44]. However, gastrins have not previous-
ly been postulated to render cells resistant to apoptosis induced by
hypoxia. Using ﬂow cytometry, the effect of hypoxia on apoptosis of
gastrin knockdown and scrambled control LoVo cell lines was assayed.
These experiments were conducted on cells incubated in low-serum
(1% FBS) medium, since it has previously been demonstrated that
serum starvation induces apoptosis in LoVo cells [45]. In both gastrin
knockdown clones, exposure to hypoxia resulted in a signiﬁcantly
higher ratio of early apoptotic cells compared to scrambled controls.
Since knocking down gastrin expression sensitises LoVo cells to
hypoxia-induced apoptosis, up-regulation of endogenous gastrins by
hypoxia is likely to be responsible for the intrinsic resistance to
hypoxia-induced apoptosis in this cell line.
The ability of exogenous PG, Ggly and Gamide to restore resistance
to hypoxia-inducible apoptosis in the gastrin knockdown LoVo clones
was investigated. Treatment with either of the non-amidated gastrins
produced a partial, but signiﬁcant, rescue of the knockdown phenotype.
In contrast, the apoptotic index of hypoxic gastrin knockdown LoVo
clones was unchanged by treatment with Gamide. Although mRNA
encoding the CCK2R, which mediates the physiological effects of
Gamide, has been detected in some clones of LoVo cells [22,29], and
treatmentwith 10 nMGamide has been reported to stimulate both pro-
liferation [46,47] and apoptosis [48] in a CCK2R-dependent manner,
other clones do not express a functional CCK2R [30,31]. The lack of a
Gamide-stimulated response indicates at the very least that CCK2R on
LoVo cells is not coupled to intracellular signalling pathways involved
in the regulation of hypoxia-inducible apoptosis.
To study the long-term effects of inhibition of gastrin expression on
tumour adaptation to pronounced chronic hypoxia in vivo, heterotopic
tumour xenografts derived from LoVo cells stably expressing either
gastrin shRNA or scrambled shRNA were grown subcutaneously in op-
posite ﬂanks of SCID mice. Subcutaneous LoVo xenografts have previ-
ously been shown to exhibit a pattern of growth that closely reﬂects
the biological and kinetic properties of human colonic adenocarcinoma
[36]. Half of the mice were exposed to continuous inspiratory hypoxia
(10% O2) during tumour growth. The scrambled and gastrin knockdown
xenografts exhibited similar tumour growth parameters in both the
normoxia and hypoxia groups. However, macroscopic skin changes
indicating underlying tumour necrosis were visible at day 21 in 6 of 9gastrin knockdown xenografts in the hypoxia group only. Tumour ne-
crosis was conﬁrmed by examination of H&E-stained tumour sections,
and the necrotic areawas signiﬁcantly greater in the gastrin knockdown
tumours than in the scrambled tumours. In other words the presence of
PG-derived peptides protected the tumour xenografts from necrosis.
In both scrambled and gastrin knockdown tumours necrotic, not
apoptotic, cell death predominates. The presence of macroscopic skin
changes characteristic of underlying necrosis only in 6 of 9 gastrin
knockdown xenografts under hypoxia indicates that necrotic pathways,
additional to the apoptotic pathways activated equally in all groups,
have been activated to a greater extent in these animals than in the
other three groups. In scrambled xenografts, cells may resist hypoxia-
induced apoptosis until energy stores are exhausted and then undergo
necrosis, rather than apoptosis, because of ATP depletion [49]. In gas-
trin knockdown xenografts, the presence of positive staining for ac-
tive caspase-3 suggests that cell death occurring in necrotic areas is
at least partly the result of the activation of apoptosis. However,
the failure of the majority of cells in the peri-necrotic zone to com-
plete the apoptotic programme and activate caspase-3 may reﬂect
the major inﬂuence that the severity of the hypoxic insult has on
cell death fate [42].
How do PG-derived peptides protect CRC cells against hypoxia? One
possible mechanism [50] is based on the observations that gastrins se-
lectively bind two ferric ions, and that transferrin saturation positively
correlates with circulating gastrin concentrations in mice and humans.
The hypothesis was therefore advanced that circulating gastrins act as
chaperones for the uptake of ferric ions by apo-transferrin. Presumably
the increased availability of transferrin-bound ferric ions is in some as
yet undeﬁned way responsible for the protection of CRC cells against
hypoxia.
In summary, this is the ﬁrst study to demonstrate in vivo that
hypoxia-inducible gastrin gene expression represents a signiﬁcant
adaptive response to chronic hypoxia in human CRC tumours. Exposure
of mice to continuous inspiratory hypoxia for 21 days resulted in a two-
fold expansion in the fraction of chronically hypoxic viable cells, and
revealed signiﬁcant differences between scrambled and gastrin knock-
down tumours. The major ﬁnding of this study is that tumour necrosis
was signiﬁcantly increased by knocking down gastrin gene expression,
although there was no difference in the proportion of cells undergoing
apoptosis in the peri-necrotic zone. The corollary of this ﬁnding is that
non-amidated gastrin antagonists, such as bismuth ions, may be useful
as a novel treatment for carcinoma of the colon.
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